- Conditions
- Frequent Heartburn
- Interventions
- Rabeprazole sodium
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 33
- States / cities
- Scottsdale, Arizona • Griffin, Georgia • Lawrenceville, Georgia + 29 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 793–816
of 3,698
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Nocturia
- Interventions
- Desmopressin, Placebo
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 51
- States / cities
- Anniston, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 45 more
- Conditions
- Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
- Interventions
- Inebilizumab, Blinatumomab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Hialeah, Florida + 13 more
- Conditions
- Grade 3a Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Refractory Follicular Lymphoma
- Interventions
- Ibrutinib, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 4 more
- Conditions
- Diabetic Neuropathy, Painful
- Interventions
- pregabalin (Lyrica), Placebo
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 633 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 150
- States / cities
- Birmingham, Alabama • Northport, Alabama • Gilbert, Arizona + 120 more
- Conditions
- System; Sclerosis, Diffuse Cutaneous Systemic Sclerosis
- Interventions
- Belumosudil (KD025), Placebo
- Drug
- Lead sponsor
- Kadmon, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 20 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- Cabozantinib tablets, Everolimus (Afinitor) tablets
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 658 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 46 more
- Conditions
- Atopic Dermatitis
- Interventions
- Lebrikizumab, Placebo
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 58
- States / cities
- Scottsdale, Arizona • Bryant, Arkansas • Rogers, Arkansas + 51 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Pemetrexed, Cisplatin, Etoposide, Vinorelbine, Paclitaxel, Carboplatin, Thoracic Radiation Therapy (TRT)
- Drug · Radiation
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 598 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more
- Conditions
- Migraine
- Interventions
- air insufflation, placebo
- Procedure
- Lead sponsor
- Carrick Institute for Graduate Studies
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Muraglitazar, Pioglitazone
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 112
- States / cities
- Birmingham, Alabama • Columbiana, Alabama • Madison, Alabama + 109 more
- Conditions
- Attenuated Familial Adenomatous Polyposis, Familial Adenomatous Polyposis
- Interventions
- Erlotinib, Erlotinib Hydrochloride
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Ann Arbor, Michigan • Rochester, Minnesota + 4 more
- Conditions
- Atopic Dermatitis, Eczema, Atopic
- Interventions
- PF-08049820, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Huntington Beach, California + 10 more
- Conditions
- Pregnancy, Autistic Disorder, Folic Acid Deficiency
- Interventions
- Prenatal supplement
- Dietary Supplement
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Coronary Artery Disease
- Interventions
- Placebo & Aspirin, Clopidogrel & Aspirin, Prasugrel & Aspirin
- Drug
- Lead sponsor
- Baim Institute for Clinical Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25,682 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 178
- States / cities
- Fairhope, Alabama • Gilbert, Arizona • Phoenix, Arizona + 143 more
- Conditions
- Lung Cancer
- Interventions
- Induction Carboplatin, Induction Paclitaxel, Resection, Consolidation Carboplatin, Radiation Therapy, Consolidation Paclitaxel
- Drug · Procedure · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2016
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 17 more
- Conditions
- Multiple Sclerosis
- Interventions
- Cladribine, Placebo, Interferon-beta (IFN-beta)
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 21
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 18 more
- Conditions
- Advanced Solid Tumors
- Interventions
- ASP8374, Pembrolizumab
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Sacramento, California + 14 more
- Conditions
- Vitiligo
- Interventions
- TEV-53408
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Hot Springs, Arkansas • Fremont, California + 10 more
- Conditions
- Cardiopulmonary
- Interventions
- Not listed
- Lead sponsor
- Prolaio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2027
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Palo Alto, California • San Francisco, California + 11 more
- Conditions
- Healthy
- Interventions
- Omeprazole, Lactobacillus rhamnosus GG, Placebo
- Drug · Dietary Supplement
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Urothelial Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma
- Interventions
- Pembrolizumab, Sonidegib
- Biological · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma, Cervical Carcinosarcoma, Cervical Squamous Cell Carcinoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Fallopian Tube Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Squamous Cell Carcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Female Reproductive System Neoplasm, Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Epithelial Tumor, Malignant Ovarian Mucinous Tumor, Malignant Peritoneal Neoplasm, Malignant Solid Neoplasm, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Unresectable Melanoma, Uterine Corpus Carcinosarcoma
- Interventions
- Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel, Pharmacological Study
- Biological · Other · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more
- Conditions
- Non-melanomatous Skin Cancer
- Interventions
- acitretin, placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 11
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 8 more